Article
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
Antimicrobial agents and chemotherapy - 1 Dec 2009
Jugheli Levan, Bzekalava Nino, de Rijk Pim, Fissette Krista, Portaels Françoise, Rigouts Leen
Abstract excerpt
The aminoglycosides kanamycin and amikacin and the macrocyclic peptide capreomycin are key drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB). The increasing rates of resistance to these drugs and the possible cross-resistance between them are concerns for MDR-TB therapy. Mutations in the 16S rRNA gene (rrs) have been associated with resistance to each of the drugs, and mutations of the tlyA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.